Cyclophosphamide-Mediated Tumor Priming for Enhanced Delivery and Antitumor Activity of HER2-Targeted Liposomal Doxorubicin (MM-302)

Geretti, Elena; C. Leonard, Shannon; Dumont, Nancy; Lee, Helen; Zheng, Jinzi; De Souza, Raquel; F. Gaddy, Daniel; W. Espelin, Christopher; A. Jaffray, David; Moyo, Victor; B. Nielsen, Ulrik; J. Wickham, Thomas; S. Hendriks, Bart

doi:10.1158/1535-7163.mct-15-0314

Public

Cyclophosphamide-Mediated Tumor Priming for Enhanced Delivery and Antitumor Activity of HER2-Targeted Liposomal Doxorubicin (MM-302)

Published in Molecular Cancer Therapeutics • Jul 10, 2015

Authors:

Elena Geretti

Shannon C. Leonard

Nancy Dumont

Abstract

Given the bulky nature of nanotherapeutics relative to small molecules, it is hypothesized that effective tumor delivery and penetration are critical barriers to their clinical activity. HER2-targeted PEGylated liposomal doxorubicin (MM-302, HER2-tPLD) is an antibody-liposomal drug conjugate designe...

Subject

Cyclophosphamide

Doxorubicin

Pharmacology

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!